Table 2 Effects of the KEβHB versus placebo drinks on lipid profile stratified by habitual intake of saturated fat

Total cholesterol (mg/dL × min)

KEβHB (n = 18)

776.0 ± 26.97

791.2 ± 23.18

Placebo (n = 18)

780.9 ± 30.94

788.8 ± 25.44

Δ (KEβHB-placebo)

−4.86 (−16.48, 6.77)

2.32 (−5.21, 9.85)

d

0.17

0.10

p

0.36

0.50

HDL cholesterol (mg/dL × min)

KEβHB (n = 18)

564.0 ± 34.87

577.7 ± 28.56

Placebo (n = 18)

565.1 ± 32.22

586.4 ± 31.68

Δ (KEβHB-placebo)

−1.14 (−10.59, 8.30)

−8.72 (−18.50, 1.06)

d

0.03

0.29

p

0.79

0.07

LDL cholesterol (mg/dL × min)

KEβHB (n = 18)

698.8 ± 47.74

717.6 ± 29.34

Placebo (n = 18)

700.7 ± 57.96

708.0 ± 31.56

Δ (KEβHB-placebo)

−1.81 (−18.11, 14.48)

9.64 (−3.41, 22.70)

d

0.04

0.32

p

0.80

0.13

Remnant cholesterol (mg/dL × min)

KEβHB (n = 18)

472.6 ± 48.73

460.5 ± 106.7

Placebo (n = 18)

493.2 ± 44.43

482.1 ± 93.09

Δ (KEβHB-placebo)

−20.68 (−40.30, −1.06)

−21.57 (−56.25, 13.11)

d

0.44

0.22

p

0.04*

0.19

Triglycerides (mg/dL × min)

KEβHB (n = 18)

732.9 ± 53.29

710.2 ± 118.1

Placebo (n = 18)

756.1 ± 48.69

734.6 ± 101.1

Δ (KEβHB-placebo)

−23.19 (−45.22, −1.16)

−24.39 (−63.61, 14.83)

d

0.45

0.22

p

0.04*

0.19

Triglycerides to HDL cholesterol ratio

KEβHB (n = 18)

63.1 ± 61.92

98.9 ± 91.19

Placebo (n = 18)

77.9 ± 54.37

106.3 ± 58.48

Δ (KEβHB-placebo)

−14.81 (−37.58, 7.97)

−7.41 (−41.47, 26.64)

d

0.25

0.10

p

0.17

0.6